Autoantibody screening enables early diagnosis—even before the first symptoms appear. This reduces the risk of serious complications such as ketoacidosis and allows treatment to begin earlier. At the same time, the development of beta cell replacement therapies based on stem cells is progressing. Innovative techniques such as gene editing and bioencapsulation are opening up new paths, and initial therapeutic approaches are already being tested in studies.
Modern next-generation insulins and advances in automated insulin delivery (AID) systems are improving blood sugar control and significantly reducing the daily burden on patients.
The US Food and Drug Administration has approved the drug Teplizumab: this immunotherapy can delay the onset of the disease. Other immune-based approaches show promising potential for preserving beta cell function.
These advances open up new perspectives for prevention, therapy, and quality of life for people with type 1 diabetes.
Original publication:
Prof Anette-Gabriele Ziegler, Prof Eda Cengiz, Prof Thomas W H Kay: The future of type 1 diabetes therapy. The Lancet (2025). DOI: https://doi.org/10.1016/S0140-6736(25)01438-2
